RxDoctor Payments Data

Nekea Franklin

Nurse Practitioner · Wayne, MINPI 1659710861

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $14,161 of the $17,843 with a category attached, or 79.4%. It is spread thinly across 57 manufacturers, the largest accounting for just 23.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $7,834 and has fallen 98.7% since, to $104 in 2025. Among nurse practitioner clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$17,843in general payments, 2019–2025

Across 878 payments — averaging $20.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biohaven Pharmaceuticals, Inc.$4K
  • AbbVie$3K
  • Bristol Myers Squibb$1K
  • Eisai Inc.$944
  • SK Life Science, Inc.$847
  • Amgen$625
  • plus $7K from 51 others

What the payments were for

  • Speaking & faculty fees$2,94016%
  • Travel & lodging$6564%
  • Food & beverage$14,16179%
  • Education$850%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Biohaven Pharmaceuticals, Inc.19$4,133
AbbVie(2 entities)262$2,989
Bristol Myers Squibb73$1,094
Eisai Inc.57$944
SK Life Science, Inc.41$847
Amgen(2 entities)39$625
Catalyst Pharmaceuticals, Inc.32$571
Supernus Pharmaceuticals, Inc.29$481
Lundbeck LLC17$387
Jazz Pharmaceuticals Inc.18$372
UCB, Inc.27$370
Argenx US, Inc.19$366
Genentech USA, Inc.19$362
Sanofi13$318
Neurelis, Inc.16$307
Amneal Pharmaceuticals LLC15$301
Neurocrine Biosciences, Inc.14$284
Novartis14$253
Biohaven Pharmaceutical Holding Company Ltd.20$186
Sunovion Pharmaceuticals Inc.13$185
Merz Pharmaceuticals, LLC7$167
Biogen9$164
Otsuka America Pharmaceutical, Inc.2$142
ANI Pharmaceuticals, Inc.6$134
Ipsen Biopharmaceuticals, Inc6$133
AstraZeneca4$127
Alnylam Pharmaceuticals Inc.6$111
Teva Pharmaceuticals USA, Inc.5$105
Acadia Pharmaceuticals Inc5$101
Pfizer6$98
CSL Behring5$96
Upsher-smith Laboratories LLC5$87
EMD Serono, Inc.4$86
Tanabe Pharma America, Inc.4$77
E.r. Squibb & Sons, L.L.C.4$76
Johnson & Johnson3$68
Harmony Biosciences LLC3$65
Bausch Health US, LLC4$63
Lilly USA, LLC3$60
Sumitomo Pharma America, Inc.7$59
Takeda Pharmaceuticals U.S.A., Inc.2$58
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)3$54
Orphalan Inc1$38
Revance Therapeutics, Inc.1$37
Arbor Pharmaceuticals, Inc.2$34
Avion Pharmaceuticals2$31
Alfasigma USA, Inc.2$28
Kyowa Kirin, Inc.1$26
Idorsia Pharmaceuticals US Inc1$22
TG Therapeutics, Inc.1$21
Aprecia Pharmaceuticals, LLC1$17
Axsome Therapeutics, Inc.1$16
Vanda Pharmaceuticals Inc.1$14
Grifols USA, LLC1$14
Mallinckrodt Hospital Products Inc.1$14
Endo Pharmaceuticals Inc.1$14
GRT US Holding, Inc.1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$17,843 in reported general payments places this provider in the 95th percentile of 3,351 nurse practitioner providers in Michigan.

See all nurse practitioner providers in Michigan

Medicare billing

Part B allowed, 2024
$5,967
Medicare patients
23
Services billed
439

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AptiomEslicarbazepine Acetate71$98,960
QuliptaAtogepant51$58,957
UbrelvyUbrogepant34$54,637
FycompaPerampanel45$53,721
XcopriCenobamate30$38,922
Nurtec OdtRimegepant Sulfate20$27,500
Glatiramer Acetate14$23,443
VraylarCariprazine Hcl13$17,675
Aimovig AutoinjectorErenumab-Aooe15$12,148
Dalfampridine ErDalfampridine13$11,573
Lacosamide53$5,282
Pregabalin188$3,157
Sumatriptan Succinate65$2,758
Clobazam20$1,661
Gabapentin94$1,352

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieQulipta, Ubrelvy, Vraylar$2,989$131,26998 claims
Sunovion Pharmaceuticals Inc.Aptiom$185$98,96071 claims
Eisai Inc.Fycompa$944$53,72145 claims
SK Life Science, Inc.Xcopri$847$38,92230 claims
PfizerNurtec Odt$98$27,50020 claims
Upsher-smith Laboratories LLCTopiramate$87$25840 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,351 nurse practitioner providers in Michigan.

Other nurse practitioner in Wayne

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →